PRESS RELEASE
Montpellier, June 30, 2021
NFL BIOSCIENCES RISE 5.0 M € FOLLOWING SUCCESS
OF ITS STOCK MARKET INTRODUCTION
SUR EURONEXT GROWTH PARIS®
- Offer 100% subscribed
- Offer price set at € 3.80 per share
- Capital increase for a gross amount of € 5 million
- Settlement delivery on July 2, 2021 and start of trading on Euronext Growth Paris on July 5, 2021
NFL Biosciences SA, a biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, announces the success of its IPO on Euronext Growth Paris® (ISIN: FR0014003XT0, MNEMO: ALNFL).
The operation benefited from subscriptions from historical shareholders, institutional investors and individual investors, sensitive to the global impact on public health of potential innovative treatments, prescription, of natural origin, in the field of addictions and addictions.
For Ignacio Faus, Managing Director of NFL Biosciences: “ We would like to thank all the shareholders, institutional and individuals, who supported us in this capital increase. We will be able to expand the organization with recruitments to support the progress of the clinical study of NFL-101, and initiate the development of the NFL-201 and NFL-301 programs, for the treatment of cannabis addiction and reduction in alcohol consumption. “.
Bruno Lafont, Deputy CEO adds: “ We will now be able to launch the Phase II / III study on 318 patients of our drug candidate NFL-101, already approved in Australia, a country recognized for the quality of its research, and where two centers will be opened in Tasmania during the third quarter 2021. We also intend to open recruitment centers in Europe. “.
Result of the Offer
In the context of the public offer in France made in the form of an open price offer (the ” Open Price Offer “Or the” OPO “) And the global placement for institutional investors (the” Placement Global “) (Together the” Offer ”), A total of 1,315,842 new shares (the“ New Shares ”) were allocated:
- 486,205 New Shares in the Open Price Offer. Orders A1 and A2 have been allocated in full;
- 829,637 New Shares in the Global Placement.
The Board of Directors of NFL Biosciences, meeting today, therefore noted the partial exercise of the extension clause and set the price of the Open Price Offer at 3.80 euros per share.
The gross proceeds from the issuance of the New Shares amounted to approximately € 5 million.
Use of funds raised
The funds raised will allow NFL Biosciences to accelerate its development through:
- the completion of the Phase II / III study of its drug candidate NFL-101;
- recruiting talent to strengthen the organization;
- the initiation of the NFL-201 and NFL-301 programs, for the treatment of cannabis addiction and the reduction of alcohol consumption.
Next steps
- Payment delivery: July 2, 2021
- Admission of the shares to the Euronext Growth Paris® market and first negotiations: July 5, 2021
Characteristics of the action
Label: NFL Biosciences
Mnemonic code: ALNFL
Code ISIN FR0014003XT0
ICB Classification : 20103010 – Biotechnologie
LEI: 9695006VJWNTN4UNHA27
Eligibility: PEA and PEA-PME
Breakdown of capital and voting rights
| Before operation | After operation | |||||||
| Undiluted basis | Diluted basis(1) | Undiluted basis | Diluted basis(1) | |||||
| In number of actions | On % | In number of actions | On % | In number of actions | On % | In number of actions | On % | |
| Joël BESSE | 979 690 | 24,99% | 1 229 690 | 20,35% | 1 111 253 | 21,23% | 1 361 253 | 18,50% |
| LAFONT family | 374 390 | 9,55% | 1 124 390 | 18,60% | 377 679 | 7,22% | 1 127 679 | 15,32% |
| Gérard LEDUC | 76 550 | 1,95% | 1 076 550 | 17,81% | 76 550 | 1,46% | 1 076 550 | 14,63% |
| MERAU family | 653 050 | 16,66% | 778 050 | 12,87% | 666 206 | 12,73% | 791 206 | 10,75% |
| Eric MOREL D’ARLEUX | 333 330 | 8,51% | 333 330 | 5,52% | 372 803 | 7,12% | 372 803 | 5,07% |
| Nicolas family | 275 320 | 7,03% | 275 320 | 4,56% | 275 320 | 5,26% | 275 320 | 3,74% |
| Other private | 1 226 440 | 31,30% | 1 226 440 | 20,29% | 1 242 358 | 23,73% | 1 242 358 | 16,88% |
| Floating | – | 0,00% | – | – | 1 112 443 | 21,25% | 1 112 443 | 15,12% |
| Total | 3 918 770 | 100,00% | 6 043 770 | 100,00% | 5 234 612 | 100,00% | 7 359 612 | 100,00% |
(1) Post exercise of:
– 100,000 2018 share subscription warrants (BSA) that can be exercised until July 2, 2023 at a price of 0.50 euros per share, one warrant giving the right to subscribe to 10 shares with a par value of 0.03 euros;
– 12,500 2019 BSA that can be exercised until March 8, 2026 at a price of € 0.30 per share, one warrant giving the right to subscribe to 10 shares with a par value of € 0.03;
– 50,000 share subscription warrants for business creators (BSPCE) 2018 that can be exercised until July 2, 2025 at a price of 0.10 euros per share, one warrant giving the right to subscribe to 10 shares of 0.03 nominal euro;
– 50,000 BSPCE 2019 that can be exercised until March 8, 2026 at a price of € 0.30 per share, one warrant giving the right to subscribe to 10 shares with a par value of € 0.03.
Conservation commitments
As a reminder, commitments to retain Company shares have been signed by a quota of shareholders representing 100% of the existing shares and voting rights of the Company. Said shareholders undertake to keep the shares they hold before the transaction up to:
- 100% of said shares for a period of 6 months from the admission of the Company’s shares to the Euronext Growth Paris® market, and
- 50% for a period of 6 months starting at the end of the first period of 6 months.
-
20210630_NFLBiosciences_CP_Results-IPO_EN_DEF
